torcetrapib has been researched along with Hypertension in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hermann, M; Ruschitzka, FT | 1 |
| Arca, M; Asselbergs, FW; Boekholdt, SM; Cambien, F; Casas, JP; Cooper, J; D'Agostino, RB; Deanfield, J; Dullaart, RP; Ebrahim, S; Ford, I; Freeman, D; Gaudio, C; Goto, A; Gudnason, V; Hingorani, AD; Horne, BD; Humphries, SE; Isaacs, A; Kakko, S; Kastelein, JJ; Kauma, H; Kesäniemi, YA; Khaw, KT; Kivimaki, M; Kumari, M; Lawlor, DA; Li, TY; Marmot, M; McCaskie, P; McCormack, V; Navis, G; Nicaud, V; Okumura, K; Ordovas, J; Packard, C; Palmer, LJ; Paulweber, B; Pencina, M; Poirer, O; Quagliarini, F; Ricketts, SL; Sandhofer, A; Sandhu, MS; Sattar, N; Savolainen, MJ; Shah, T; Smeeth, L; Smith, GD; Sofat, R; Sorli, JV; Talmud, PJ; Thompson, JF; van der Harst, P; van Duijn, CM; Van Gilst, WH; van Veldhuisen, DJ; Vasan, RS; Wareham, N; Witteman, JC; Yokoyama, S | 1 |
| Funder, JW | 2 |
| Bénardeau, A; Capponi, AM; Clerc, RG; Funder, JW; Garriz, JM; Hainaut, E; Hoflack, JC; Niesor, EJ; Perez, A; Pflieger, P; Stauffer, A; Weibel, F | 1 |
| Atzmon, G; Barzilai, N; Crandall, JP; Schechter, CB | 1 |
| Besler, C; Bigler, L; Dörries, C; Hermann, M; Lüscher, TF; Ruschitzka, F; Shaw, SG; Simic, B; Stalder, U | 1 |
| Arsenault, BJ; Boekholdt, SM; Kastelein, JJ; Tardif, JC | 1 |
| Hall, JE; Jones, DW | 1 |
| Merrick, GS; Moyad, MA | 1 |
| Chapman, MJ; Guérin, M; Kontush, A | 1 |
5 review(s) available for torcetrapib and Hypertension
| Article | Year |
|---|---|
The hypertension peril: lessons from CETP inhibitors.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hypertension; Quinolines | 2009 |
Aldosterone, sodium, and hypertension: lessons from torcetrapib?
Topics: Aldosterone; Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Humans; Hypercholesterolemia; Hypertension; Quinolines; Sensitivity and Specificity; Sodium | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
World Hypertension Day 2007.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Global Health; Humans; Hypertension; Quinolines; Risk Factors | 2007 |
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypertension; Quinolines | 2008 |
7 other study(ies) available for torcetrapib and Hypertension
| Article | Year |
|---|---|
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Topics: Anticholesteremic Agents; Biomarkers; Blood Pressure; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Electrolytes; Genotype; Humans; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Polymorphism, Single Nucleotide; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; White People | 2010 |
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Aldosterone; Amides; Angiotensin II; Animals; Anticholesteremic Agents; Blood Pressure; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP11B2; Cytosol; Enzyme Induction; Esters; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Gene Expression Profiling; Humans; Hypertension; NAV1.1 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Quinolines; Rats; Rats, Inbred SHR; RNA, Small Interfering; Sodium Channels; Structure-Activity Relationship; Sulfhydryl Compounds | 2010 |
Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Genotype; Heterozygote; Homozygote; Humans; Hypertension; Male; Prevalence; Quinolines | 2010 |
Torcetrapib impairs endothelial function in hypertension.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; Bosentan; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Hypertension; Immunohistochemistry; Intercellular Adhesion Molecule-1; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Quinolines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Renin-Angiotensin System; Sulfonamides; Superoxides; Vascular Cell Adhesion Molecule-1 | 2012 |
De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
Topics: Animals; Anticholesteremic Agents; Endothelium, Vascular; Hypertension; Male; Quinolines | 2012 |
New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Hypertension; Mutation; Quinolines; Treatment Failure | 2007 |
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Drug Industry; Exercise Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Patient Education as Topic; Quinolines; Risk Reduction Behavior; Smoking Cessation; Stress, Psychological; United States; Urologic Diseases; Weight Loss | 2007 |